Evidence map›Paper›PMID 40629339›Full record

ArticleCell communication and signaling : CCS2025

JC124 confers multimodal neuroprotection in epilepsy by suppressing NLRP3 inflammasome activation: evidence from animal and human neuronal models.

Peng Zhang, Zhipeng Li, Minxue Liang, Jinxian Yuan, Jinyu Zhou, Jie Zhang, Jing Deng, Yalan Chen, Hao Tang, Chengjie Xu and 6 more

Abstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Peng Zhang *Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China. peng.zhang.ac@foxmail.com.ORCID http://orcid.org/0000-0001-8071-3729
Zhipeng Li *Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.ORCID http://orcid.org/0009-0002-3819-9070
Minxue LiangDepartment of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.ORCID http://orcid.org/0000-0003-4840-0559
Jinxian YuanDepartment of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Jinyu ZhouDepartment of Rehabilitation Sciences and Physiotherapy, University of Antwerp, Antwerp, 2610, Belgium.ORCID http://orcid.org/0000-0002-4803-9559
Jie ZhangDepartment of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Jing DengHealth Medical Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Yalan ChenDepartment of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Hao TangDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Chengjie XuDepartment of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, China.
Chenjun ShiDepartment of Respiratory Medicine, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, 400042, China.
Limin MaDepartment of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Qiankun LiuDepartment of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Yong LiuDepartment of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
Yangmei ChenDepartment of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China. chenym1997@foxmail.com.
Hui ZhangKey Laboratory of Major Brain Disease and Aging Research (Ministry of Education), Chongqing Medical University, Chongqing, 400016, China. hui_zhang016@163.com.ORCID http://orcid.org/0009-0005-7364-5138

Funding

China Postdoctoral Science Foundation 2024MD764061National Natural Science Foundation of China 81901330National Natural Science Foundation of China 82471474
6 · The paper itself

Abstract

backgroundDespite continuous development of antiseizure medications (ASMs), global seizure control rates remain unsatisfactory, highlighting the urgent need for novel ASMs targeting distinct pathophysiological mechanisms. Inhibition of NLRP3 inflammasome activation represents an emerging strategy to simultaneously attenuate seizures and associated neuropsychiatric comorbidities. Therefore, this study investigates whether JC124, a novel NLRP3 inflammasome inhibitor, exerts neuroprotective effects in kainic acid (KA)-induced epileptic mice and in human induced pluripotent stem cell (hiPSC)-derived neurons stimulated by lipopolysaccharide (LPS) and adenosine triphosphate (ATP).

methodsSummary-based Mendelian Randomization (SMR) was used to analyze the association between NLRP3 alleles and epilepsy susceptibility. NLRP3 knockout mice were generated, and then epileptic mice induced by intrahippocampal KA injection were administered JC124 (50 mg/kg, intraperitoneal) once daily for 28 days. The spontaneous recurrent seizures, hippocampal local field potential, depressive-like behavior, cognitive dysfunction, and locomotor ability of mice were evaluated. The brain tissues of the mice were collected for Western blotting, immunohistochemistry, immunofluorescence labeling, enzyme-linked immunosorbent assay, transmission electron microscopy, and morphological staining. The binding capacity of JC124 to the human NLRP3 protein was assessed using molecular docking and molecular dynamics simulations. hiPSC-derived neurons were used to explore the neuroprotective effects of JC124 against inflammatory injury in human neurons.

resultsIn this study, a positive correlation was identified between the expression of the NLRP3 gene and the susceptibility to epilepsy through SMR analysis. JC124 intervention markedly inhibited seizures and improved depressive-like behavior and cognitive dysfunction. It also reduced hippocampal neuronal loss, neuronal pyroptosis, microgliosis, and astrogliosis. Importantly, the neuroprotective effects of JC124 in KA-induced epileptic mice were mediated through the inhibition of the NLRP3 inflammasome. JC124 inhibited neuroinflammation and oxidative stress in KA-treated NLRP3 wild-type mice, but not in KA-treated NLRP3 knockout mice. Furthermore, JC124 bound directly to the human NLRP3 protein and alleviated neuroinflammation and oxidative stress in hiPSC-derived neurons stimulated by LPS and ATP.

conclusionsThese findings indicate that inhibiting the activation of the NLRP3 inflammasome with JC124 represents a potentially safe and innovative therapeutic strategy to mitigate neuroinflammation and oxidative stress in epilepsy and to alleviate seizures and associated neuropsychiatric comorbidities.

Indexed as

EpilepsyInflammasomesNeuronsNeuroprotectionNeuroprotective AgentsNLR Family, Pyrin Domain-Containing 3 ProteinAnimalsDisease Models, AnimalHumansInduced Pluripotent Stem CellsKainic AcidLipopolysaccharidesMaleMiceMice, Inbred C57BLMice, KnockoutInflammasomesKainic AcidLipopolysaccharidesNeuroprotective AgentsNLR Family, Pyrin Domain-Containing 3 ProteinEpilepsyJC124NeuroinflammationNeuropsychiatric comorbiditiesNLRP3 inflammasomeOxidative stress

Identifiers

PMID40629339
PMCPMC12239262

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.